Navigation Links
Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:9/25/2007

- Study Will Assess Drug's Benefit, Alone and With Lipitor(R), in Overweight or Obese Patients with High Cholesterol and Triglycerides -

HAYWARD, Calif., Sept. 25 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug's effect on dyslipidemia, insulin-resistance and obesity.

Preclinical and clinical testing of MBX-8025 indicates that the drug has the potential to improve a number of lipid parameters that are abnormal in different types of dyslipidemia, including high LDL (or "bad") cholesterol, high Apo B-100 (the atherogenic lipoprotein), low HDL (or "good") cholesterol and high triglycerides (fats). In addition, MBX-8025 has been shown to exhibit positive effects on insulin sensitization and body weight. The randomized, double-blind Phase 2 trial will assess the potential of the drug alone and in combination with Lipitor(R) (atorvastatin).

"Although high LDL levels are widely treated as a risk factor for heart disease, many patients are unable to reach increasingly low LDL targets on a statin alone. Additionally, existing drugs do a poor job of targeting the entire range of different lipid disorders that contribute to cardiac risk. We believe this trial will provide us crucial evidence in assessing the ability of MBX-8025 to lower Apo B-100, LDL and triglyceride levels, as well as raise HDL levels, improve insulin sensitivity and reduce body weight," said David B. Karpf, M.D., the chief medical officer of Metabolex. "In addition, we are testing the drug in conjunction with Lipitor, the best-selling lipid-lowering drug in the world, to determine whether combination therapy with a statin will be well tolerated and lead to even better results."

The study will
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 04, 2015 Research and Markets ... "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" report ... the clinic under the trade name of Bondronat in ... in 1996, sodium ibandronate was approved by the FDA to ... under the trade name of Boniva. However, since drug makers ...
(Date:9/3/2015)... , Sept. 3, 2015  Cipla, a global pharmaceutical ... everyday needs of all patients, today announced that its ... to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and ... closing conditions, is valued at $550 million and will ... these transactions is over $200 million for the year ...
(Date:9/3/2015)... About Vision Care Products ... this report are Rx lenses, frames, contact lenses, ... used by consumer for vision correction and vision ... contact lenses require a prescription for purchase while ... that can be purchased like any other apparel ...
Breaking Medicine Technology:Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Vision Care Market in the US 2015-2019 2
... May 5 A voluntary recall has,been issued ... and,labeled with the Cardinal Health brand name. Hydrox ... individual mouthwash bottles and,those contained within Cardinal Health ... and been found positive for Burkholderia,cepacia (B. cepacia). ...
... Delivered Within Pre-Determined ... and Standard Dosing Limitations, BRIDGEWATER, N.J., May 5 ... SoloSTAR(R) disposable insulin pen,prefilled with Lantus(R) (insulin glargine [rDNA ... the pens,accurately delivered all insulin doses within standard limits ...
Cached Medicine Technology:Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:9/4/2015)... ... September 04, 2015 , ... FiltersFast.com, ... Day offer that cannot be passed up. FiltersFast.com, will ship all orders ... and water filtration product replacements. Take advantage of this promotion now through September ...
(Date:9/3/2015)... ... September 03, 2015 , ... While bariatric surgeon Michael Feiz, ... practices when preparing for a bariatric procedure, some patients have been recently asking further ... basic instructions typical for many types of surgery that should be followed in the ...
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices is known for ... does not stop at any certain demographic or segment of the population. Because ... fifteen- and ten-second TV commercials. , The closed captioning will allow people with hearing ...
(Date:9/3/2015)... ... 03, 2015 , ... Mayo School of Graduate Medical Education ... for Hospice Care (CHC) for physician Hospice and Palliative Medicine Fellowship training rotations. ... fulfilling their requirements for obtaining national Board Certification in Hospice and Palliative Medicine. ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a comprehensive survey ... and Policy Analysis has found physician leadership development training programs to be growing ... respondents said their organizations conduct some kind of physician leadership development program, another ...
Breaking Medicine News(10 mins):Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3
... ... $145,000 in grants to leading researchers at the 3rd Annual Brain Aneurysm ... to raise awareness of brain aneurysms, which affect an estimated 1 in ... September 17, 2009 from 6:00-10:00 p.m. at The Union League of Chicago, ...
... , , MILWAUKEE, Aug. 11 ... McKesson Corporation and data publishers First Data Bank and Medispan is impacting pharmacy ... Greg Ruc i nski , President & CEO for ... information business. , , "There,s a whole lot more than ...
... RIO DE JANEIRO , Aug. 11 Amilpar ( BOVESPA: AMIL3, ... announced today its results for the second quarter of 2009. , , ... Total membership stood at 3.14 million at the end ... 1Q09. , Adjusted Operating Revenues totaled R$ 1,190.4 ...
... may reduce the risk of cancer death, report investigators ... Brigham and Women,s Hospital. In the August 12 ... Association , the study,s authors also find that the ... tumors expressing the COX-2 enzyme, a characteristic of two-thirds ...
... young are most vulnerable , TUESDAY, Aug. 11 (HealthDay News) ... part to make sure that doctors and patients alike are ... use and suicide, which indicate that the risk declines steadily ... 100,000 people who took antidepressants showed that the drugs increase ...
... DETROIT, Aug. 11 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg (base), 50 mg (base) and 100 mg (base) are ...
Cached Medicine News:Health News:The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms 2Health News:The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms 3Health News:The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms 4Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 2Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 3Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 4Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 5Health News:Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009 2Health News:Postdiagnosis aspirin use reduces risk of dying from colorectal cancer 2Health News:Suicide Risk With Antidepressants Falls With Age 2Health News:Suicide Risk With Antidepressants Falls With Age 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex(R) Tablets 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: